Advanced Search

National Health (Weighted average disclosure price - main disclosure cycle) Amendment Determination 2013 (No. 1) (No. PB 18 of 2013)

Subscribe to a Global-Regulation Premium Membership Today!

Key Benefits:

Subscribe Now for only USD$40 per month.
PB 18 of 2013
National Health (Weighted average disclosure price – main disclosure cycle) Amendment Determination 2013 (No. 1)
National Health Act 1953
I, FELICTY McNEILL, First Assistant Secretary, Pharmaceutical Benefits Division, Department of Health and Ageing, delegate of the Minister for Health, make this determination under subsection 99ADB(4) of the National Health Act 1953.
Dated     7 March 2013
 
 
 
 
 
 
 
 
 
FELICTY McNEILL
 
First Assistant Secretary
Pharmaceutical Benefits Division
Department of Health and Ageing
 
1              Name of Determination
       (1)     This Determination is the National Health (Weighted average disclosure price – main disclosure cycle) Amendment Determination 2013 (No. 1).
       (2)     This Determination may also be cited as PB 18 of 2013.
2              Commencement
                This Determination commences on the day after it is registered.
 
 
3              Amendments to PB 107 of 2012
Schedule 1 amends the National Health (Weighted average disclosure price – main disclosure cycle) Determination 2012 (PB 107 of 2012).
Schedule 1             Amendments
 
 
[1]      Schedule 1
 
             omit:
 
376
Hydroxocobalamin
Injection 1 mg (as acetate) in 1 mL
Injection
Vita-B12
 
 
insert:
 
376
Hydroxocobalamin
Injection 1 mg (as acetate) in 1 mL
Injection
Vita-B12
5.62
 
[2]      Schedule 2, After
 
253
Macrogol 3350
Sachets containing powder for oral solution 13.125 g with electrolytes, 30 
Oral
Movicol
11.38
 
             insert:
 
   253A
Macrogol 3350
Sachets containing powder for oral solution 17 g, 30 
Oral
MediHealth ClearLax
11.38
 
 
 
 
[3]      Schedule 2, After
306
Morphine
Injection containing morphine sulphate 10 mg in 1 mL
Injection
Hospira Pty Limited
3.71
 
             insert:
 
   306A
Morphine
Injection containing morphine sulphate 10 mg in 1 mL (with preservative)
Injection
Morphine Sulphate Workhardt
7.42
 
[4]      Schedule 2
             omit:
 
365
Paraffin
Eye ointment, compound, containing liquid paraffin, light liquid paraffin, wool fat, white soft paraffin and retinyl palmitate, 5 g
Application to the eye
VitA-POS
 
 
insert:
 
365
Paraffin
Eye ointment, compound, containing liquid paraffin, light liquid paraffin, wool fat, white soft paraffin and retinyl palmitate, 5 g
Application to the eye
VitA-POS
5.99
 
Note
1.       All legislative instruments and compilations are registered on the Federal Register of Legislative Instruments kept under the Legislative Instruments Act 2003. See http://www.comlaw.gov.au/Home.